GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (STU:TA50) » Definitions » Interest and Commission Paid

Circio Holding ASA (STU:TA50) Interest and Commission Paid


View and export this data going back to 2019. Start your Free Trial

What is Circio Holding ASA Interest and Commission Paid?

Interest and Commission Paid only applicable to companies reporting Cash Flow from Operations in direct method.


Circio Holding ASA Business Description

Traded in Other Exchanges
Address
Saint Olavs plass, Pb. 6887, Oslo, NOR, 0130
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients. The company's pipeline candidate includes circVec and Mutant KRAS.